These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36929642)

  • 1. Application of co-processed excipients for developing fast disintegrating tablets: A review.
    Jain S; Kaur S; Rathi R; Nagaich U; Singh I
    Polim Med; 2023; 53(1):59-68. PubMed ID: 36929642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Co-processed Excipient as a Novel Method to Compound Orally Disintegrating Tablets.
    Liew KB; Hii SH; Chew YL; Ming LC; Uddin AH; Sarker ZI
    Int J Pharm Compd; 2022; 26(3):255-263. PubMed ID: 35657749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet.
    Hazdi SN; Phang HC; Ng ZQ; Chew YL; Uddin AH; Sarker ZI; Lee SK; Liew KB
    Int J Pharm Compd; 2023; 27(6):522-527. PubMed ID: 38100670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
    Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB
    Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
    Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A
    Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Coprocessed Chitin-Calcium Carbonate as Multifunctional Tablet Excipient for Direct Compression, Part 2: Tableting Properties.
    Chaheen M; Bataille B; Yassine A; Belamie E; Sharkawi T
    J Pharm Sci; 2019 Oct; 108(10):3319-3328. PubMed ID: 31145923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the Effects of Excipients in the Compounding of Amlodipine Besylate Orally Disintegrating Tablets.
    Azmi NHS; Ming LC; Uddin ABMH; Sarker ZI; Bin LK
    Int J Pharm Compd; 2022; 26(1):80-87. PubMed ID: 35081048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
    Krupa A; Jachowicz R; Pędzich Z; Wodnicka K
    AAPS PharmSciTech; 2012 Dec; 13(4):1120-9. PubMed ID: 22941425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and in vitro Evaluation of Fast Dissolving Tablets of Febuxostat Using Co-Processed Excipients.
    Kaur M; Mittal A; Gulati M; Sharma D; Kumar R
    Recent Pat Drug Deliv Formul; 2020; 14(1):48-62. PubMed ID: 31884935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluplus
    Basha M; Salama A; Noshi SH
    Drug Dev Ind Pharm; 2020 Feb; 46(2):253-263. PubMed ID: 31937139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperine fast disintegrating tablets comprising sustained-release matrix pellets with enhanced bioavailability: formulation,
    Zhu Y; Yu J; Zhou G; Gu Z; Adu-Frimpong M; Deng W; Yu J; Xu X
    Pharm Dev Technol; 2020 Jun; 25(5):617-624. PubMed ID: 32009511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients.
    Conceição J; Adeoye O; Cabral-Marques H; Concheiro A; Alvarez-Lorenzo C; Sousa Lobo JM
    AAPS PharmSciTech; 2020 Jan; 21(2):39. PubMed ID: 31897724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-processed materials testing as excipients to produce Orally Disintegrating Tablets (ODT) using binder jet 3D-printing technology.
    Ochoa E; Morelli L; Salvioni L; Giustra M; De Santes B; Spena F; Barbieri L; Garbujo S; Viganò M; Novati B; Tomaino G; Moutaharrik S; Prosperi D; Palugan L; Colombo M
    Eur J Pharm Biopharm; 2024 Jan; 194():85-94. PubMed ID: 38048887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients.
    Shi C; Zhao H; Fang Y; Shen L; Zhao L
    Drug Discov Today; 2023 Sep; 28(9):103696. PubMed ID: 37419210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Overview of Recent Patents and Patented Technology Platforms Based on Co-Processed Excipients.
    Kaushik D; Goel E; Verma R; Pandey P; Purohit D; Mittal V; Kumar K; Rahman MH
    Recent Adv Drug Deliv Formul; 2021; 15(1):3-14. PubMed ID: 33397276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
    Kokott M; Lura A; Breitkreutz J; Wiedey R
    Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
    Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
    Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Scaled-up production and application of co-processed excipient mannitol-HPMC in traditional Chinese medicine].
    Li JZ; Ruan HS; Lin X
    Zhongguo Zhong Yao Za Zhi; 2018 May; 43(10):2067-2073. PubMed ID: 29933672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation, Development, and
    Bhatia V; Dhingra AK; Dass R; Chopra B; Guarve K
    Cent Nerv Syst Agents Med Chem; 2022; 22(3):198-213. PubMed ID: 35748551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.